home / stock / torc / torc news

TORC News and Press, resTORbio Inc. From 07/23/19

Stock Information
Company Name: resTORbio Inc.
Stock Symbol: TORC
Market: NASDAQ
Website: restorbio.com
Menu
TORC TORC Quote TORC Short TORC News TORC Articles TORC Message Board
Get TORC Alerts

News, Short Squeeze, Breakout and More Instantly...
TORC - resTORbio Announces Early Completion of Enrollment of Phase 3 PROTECTOR 1 Trial with RTB101 in Clinically Symptomatic Respiratory Illness

– Company plans to announce topline data from PROTECTOR 1 by early first quarter of 2020 – – PROTECTOR 2 is planned to start in the fourth quarter of 2019, with topline data expected in mid-2020 – BOSTON, July 23, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. ...
TORC - resTORbio (TORC) Presents At American Thoracic Society International Conference - Slideshow

The following slide deck was published by resTORbio, Inc. in conjunction with this Read more ...

TORC - ResTORbio up 2% on new lead candidate data

Thinly traded micro cap resTORbio ( TORC +1.5% ) is up on below-average volume  in response to the release of more data from a Phase 2b clinical trial evaluating lead candidate RTB101 in patients at least 65 years old at high risk of respiratory tract infections (RTIs). The resu...

TORC - resTORbio Presents Additional Phase 2b Data at the American Thoracic Society International Conference for RTB101 as a Potential Immunotherapy to Reduce the Incidence of Respiratory Tract Infections in Patients 65 Years of Age and Older with Asthma

RTB101 10 mg once daily was observed to reduce the rate of laboratory-confirmed Respiratory Tract Infections (RTIs) by 78.7% (p=0.001) and the rate of all RTIs (with or without laboratory confirmation) by 66.4% (p=0.003) as compared to placebo among Phase 2b participants 65 years of age an...
TORC - resTORbio misses by $0.02

resTORbio (NASDAQ: TORC ): Q1 GAAP EPS of -$0.38 misses by $0.02 . More news on: resTORbio, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

TORC - resTORbio Reports First Quarter 2019 Financial Results and Corporate Update

Initiated first Phase 3 trial, PROTECTOR 1, of RTB101 in clinically symptomatic respiratory illness; top-line data from two pivotal Phase 3 trials expected in mid-2020 Initiated Phase 1b/2a trial of RTB101 in combination with sirolimus in Parkinson’s disease (PD) Completed ...

TORC - resTORbio Appoints Lloyd Klickstein, M.D., Ph.D., as Chief Scientific Officer

BOSTON, May 14, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today announced the appointment of Lloyd Klickstein, M.D., Ph.D., ...
TORC - resTORbio to Present RTB101 Phase 2b Clinical Trial Data at American Thoracic Society 2019 International Conference

BOSTON, May 13, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC) today announced that it will present additional results from the Phase 2b trial evaluating RTB101 (dactolisib), an oral, selective, and potent inhibitor of target of rapamycin complex 1 (TORC1), in an oral presentation ...

TORC - resTORbio (TORC) Investor Presentation - Slideshow

The following slide deck was published by resTORbio, Inc. in conjunction with this Read more ...

TORC - resTORbio Announces Initiation of Phase 3 Clinical Program of RTB101 in Clinically Symptomatic Respiratory Illness

BOSTON, May 09, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), today announced the initiation of PROTECTOR 1, the first Phase 3 trial of RTB101, an orally administered, small molecule, potent inhibitor of target of rapamycin complex 1 (TORC1). The two PROTECTOR Phase 3 trials are ...
Previous 10 Next 10